B
Brian E. Schultz
Researcher at Celera Corporation
Publications - 6
Citations - 923
Brian E. Schultz is an academic researcher from Celera Corporation. The author has contributed to research in topics: Histone deacetylase & Acetylation. The author has an hindex of 5, co-authored 6 publications receiving 824 citations.
Papers
More filters
Journal ArticleDOI
Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase
Zhengying Pan,Heleen Scheerens,Shyr-Jiann Li,Brian E. Schultz,Paul A. Sprengeler,L. Chuck Burrill,Rohan Mendonca,Michael D. Sweeney,Keana C. Scott,Paul G. Grothaus,Douglas A. Jeffery,Jill M. Spoerke,Lee Honigberg,Peter R. Young,Stacie A. Dalrymple,James T. Palmer +15 more
TL;DR: The discovery of a selective, irreversible Btk inhibitor and its efficacy in an animal model of rheumatoid arthritis is described.
Journal ArticleDOI
CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo.
Joseph J. Buggy,Z. Alexander Cao,Kathryn E. Bass,Erik Verner,Sriram Balasubramanian,Liang Liu,Brian E. Schultz,Peter R. Young,Stacie A. Dalrymple +8 more
TL;DR: Results reveal CRA-024781 to be a novel HDAC inhibitor with potent antitumor activity and an inhibition of tumor cell growth and the induction of apoptosis.
Journal ArticleDOI
Kinetics and comparative reactivity of human class I and class IIb histone deacetylases.
Brian E. Schultz,Shawn Misialek,Jiansheng Wu,Jie Tang,Marion T. Conn,Ram Tahilramani,Lance Wong +6 more
TL;DR: The reaction kinetics of isolated, recombinant human HDACs 1, 2, 3, 6, 8, and 10 were measured using a novel, continuous protease-coupled enzyme assay and the proposed reaction mechanism of acetyllysine hydrolysis by these enzymes is discussed.
Journal ArticleDOI
CRA-026440: a potent, broad-spectrum, hydroxamic histone deacetylase inhibitor with antiproliferative and antiangiogenic activity in vitro and in vivo
Z. Alexander Cao,Kathryn E. Bass,Sriram Balasubramanian,Liang Liu,Brian E. Schultz,Erik Verner,YuQin Dai,Rafael A. Molina,Jack R. Davis,Shawn Misialek,Martin Sendzik,Christine Orr,Ling Leung,Ondine Callan,Peter R. Young,Stacie A. Dalrymple,Joseph J. Buggy +16 more
TL;DR: Results reveal CRA-026440 to be a novel HDAC inhibitor with potent antitumor activity and when used in combination with Avastin, achieved greater preclinical efficacy in HCT 116 colorectal tumor model.
Journal ArticleDOI
Discovery of novel hydroxy pyrazole based factor IXa inhibitor
Dange Vijaykumar,Paul A. Sprengeler,Michael B. Shaghafi,Jeffrey R. Spencer,Brad A. Katz,Christine Yu,Roopa Rai,Wendy B. Young,Brian E. Schultz,James W. Janc +9 more
TL;DR: Synthesis and biological data of a novel selective and efficacious factor IXa inhibitor are described along with its crystal structure in factor VIIa.